Objective: Calcitonin (Ct)-negative medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor. This study aimed to clarify its incidence, clinicopathologic characteristics, management, and treatment outcome.

Methods: We retrospectively analyzed data of patients with primary MTC. Patients were divided into two groups according to the preoperative serum Ct level (Ct-negative and Ct-positive). The demographic, pathologic, and molecular characteristics, and treatment outcomes were compared between the two groups. In the Ct-negative group, we analyzed the association between the operation type and treatment outcome.

Results: Of the total 312 patients, 24 were diagnosed with Ct-negative MTC. The rate of lymph node metastasis was significantly higher in the Ct-positive than in the Ct-negative group (47.9% vs. 0%, p<0.001). The proportion of patients with Ki-67 ≤10% was significantly higher in the Ct-negative than in the Ct-positive group (87.5% vs. 38.2%, p<0.001). Excellent response was achieved by 91.7% and 34.7% of patients in the Ct-negative and Ct-positive groups, respectively (p<0.001). In the Ct-negative group, excellent response was achieved by all female patients, but only 50% of male patients.

Conclusions: Ct-negative MTC is rare and unlikely to develop lymph node metastasis. Unilateral lobectomy tends to provide a satisfactory chance of excellent response; however, this requires further validation.

KEYWORDS
calcitonin, medullary thyroid carcinoma, calcitonin-negative medullary thyroid carcinoma, biochemical cure, neuroendocrine tumor
Introduction

Medullary thyroid carcinoma (MTC), a malignant tumor arising from thyroid parafollicular C-cells characterized by the production of calcitonin (Ct), accounts for approximately 5% of all thyroid cancers (1). It can develop as a sporadic or hereditary familial tumor (2). Although sporadic MTC is usually well differentiated, less aggressive, and has a low growth rate (3), it has unpredictable outcomes. Complete tumor excision is currently the only curative therapy; thus, early diagnosis of MTC is essential (4).

Although elevated serum Ct level can be found in hyperparathyroidism, small/large-cell lung cancer, prostate cancer, renal failure, and other conditions, it is considered a reliable biomarker for MTC diagnosis, prognosis, and recurrence (5). Usually, there is a direct relationship between serum Ct levels and tumor size (6); however, since the first report of an MTC with normal serum Ct levels (7), a few similar cases (less than 50) have been described (8–12).

Due to the rarity of Ct-negative MTC, its incidence, clinicopathologic characteristics, management, and prognosis remain unknown. Therefore, the current study aimed to clarify these questions to contribute to better understanding and improved treatment of this disease in the future.

Patients and methods

Ethical considerations

The institutional research committee approved this study. All patients provided written informed consent for all diagnostic and treatment procedures. The requirement for informed consent for participation in this study was waived due to the retrospective study design. All procedures performed in this study were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Patient selection

We retrospectively reviewed the medical records of patients with surgically treated sporadic or hereditary MTC in a tertiary medical center from January 2010 to July 2022. The inclusion criteria were as follows: age > 18 years; primary disease; and available follow-up data. Patients with a history of other malignancies were excluded (Figure 1). Information on demography, pathology, treatment, and follow-up was extracted and analyzed.

Biochemical testing

Serum Ct level was measured in all patients with suspected thyroid malignant nodules. The blood sample was drawn in the morning after overnight fasting and sent to the laboratory immediately (13). Measurement was performed using the chemiluminescent immunometric assay, and normal ranges were 0–6.4 pg/mL for women and 0–9.52 pg/mL for men. MTC with a serum Ct level of < 6.4 pg/mL in women or < 9.52 pg/mL in men was considered to be Ct-negative.

Serum carcinoembryonic antigen (CEA) levels were also measured. The normal range of CEA was 0–4.7 ng/mL.

Treatment and follow-up

In our center, fine needle aspiration is selectively used, particularly for nodules less than 10 mm in size. If MTC was diagnosed based on fine needle aspiration or serum Ct level or intraoperative frozen section, total thyroidectomy with central

---

**FIGURE 1**
Study flowchart. Ct, calcitonin; MTC, medullary thyroid carcinoma.
neck dissection was performed. Therapeutic lateral neck dissection (II–V) was implemented if there was lateral neck lymph node metastasis pathologically (14, 15). If MTC was diagnosed based on the postoperative pathologic findings, the decision on reoperation was made in consideration of the patient’s willingness, tumor’s characteristics, and surgeon’s preference (16).

RET gene mutation analysis was performed by polymerase chain reaction testing, as described previously (4, 8, 9), using the TaKaRa Ex Taq kit and ABI Prism 3100 Genetic Analyzer. Immunohistochemical analysis for CEA, chromogranin A (CgA), Ct, and Ki-67 was performed for all patients.

Patients were divided into two groups according to the preoperative serum Ct level (Ct-negative vs. Ct-positive). Treatment outcome was classified as excellent or non-excellent response. Excellent response was defined as a status of undetectable Ct and no evidence of structural disease (16). The Chi-square test was used to compare the demographic, pathologic, and molecular characteristics, and treatment outcomes between the two groups, and to analyze the association between the operation type and treatment outcome in the Ct-negative group. All statistical analyses were performed using IBM SPSS Statistics 20.0 (IBM Corp., Armonk, NY, U.S.A.). Statistical significance was set at p<0.05.

Results

A total of 312 patients were enrolled, 288 (219 women and 69 men) with a mean age of 50.7 ± 13.5 years in the Ct-positive group, and 24 (20 women and 4 men) with a mean age of 51.3 ± 9.0 years in the Ct-negative group.

The mean tumor size was 19.4 ± 12.5 mm in the Ct-positive and 15.8 ± 8.9 mm in the Ct-negative group. In the Ct-positive group, multiple tumor foci were detected in 20 patients, and papillary thyroid carcinoma coexisted in 30 patients. In the Ct-negative group, all patients had only one focus, and there were no cases of concurrent papillary thyroid carcinoma or other malignant tumors. While there were six cases of somatic RET gene mutations, with one case of familial MTC in the Ct-positive group, neither RET gene mutation nor hereditary familial MTC was detected in the Ct-negative group.

There was a statistically significant difference between the groups in the extent of surgery, with the proportion of patients undergoing extensive surgery being greater in the Ct-positive than in the Ct-negative group (p<0.001). In the Ct-positive group, all patients underwent total thyroidectomy with central neck dissection, and 88 patients also required lateral neck dissection. In the Ct-negative group, 17 patients underwent unilateral lobectomy with central neck dissection and seven patients underwent total thyroidectomy with central neck dissection. Central and lateral neck lymph node metastasis was present in 138 and 88 patients in the Ct-positive group, respectively, but in none of the patients in the Ct-negative group. The Ct-negative group had significantly lower lymph node metastasis rate (0% vs. 47.9%) and serum CEA level than the Ct-positive group (p<0.001 for both). There were no significant differences between the two groups regarding age, sex, tumor size, and other baseline parameters (all p>0.05, Table 1).

In the immunohistochemical analysis, positivity for Ct, CEA, and CgA was detected in 221, 167, and 139 patients in the Ct-positive group, and 14, 10, and seven patients in the Ct-negative group, respectively. There was a significant difference between the groups regarding the proliferative capacity; Ki-67 >10% was detected in 178 patients in the Ct-positive and in only three patients in the Ct-negative group (p<0.001, Table 2).

After the initial operation, the rate of excellent response was significantly higher in the Ct-negative than in the Ct-positive group (91.7% vs. 34.7%, p<0.001, Table 3). Only two patients in the Ct-negative group had a non-excellent response, a 67-year-old female patient with an initial tumor size of 1.0 cm and a 61-year-old female patient with an initial tumor size of 0.6 cm. However, at the last follow-up, their serum Ct levels were 34.2 pg/mL and 11.2 pg/mL, respectively, and neither of them had structurally identifiable disease.

In the subgroup analysis in the Ct-negative group, the excellent response rate was 50% among men and 100% among women, with a statistically significant difference (p=0.022). There was no significant difference in the excellent response rate according to the operation type; excellent response was achieved by six of seven patients who underwent total thyroidectomy, and by 16 of 17 patients who underwent unilateral lobectomy (p=1.000). Additionally, no significant difference was observed regarding age, tumor size, and serum CEA levels (all p>0.05, Table 4).

Discussion

This study found that, compared to typical MTC, Ct-negative MTC tended to have limited capacity of lymph node metastasis and proliferation, and a good prognosis independent of the operation extent. However, male patients might require more aggressive treatment.
Ct-negative MTC is a rare disease, most commonly described in case reports (12, 17–20). Hence, its incidence remains unknown. Frank-Raue et al. (11) identified seven nonsecretory MTCs among 839 sporadic cases for an incidence of 0.83%, while Zhou et al. (10) reported Ct-negative MTC in 12.0% of 158 MTC cases. In the current study, the incidence was 7.8%. The wide incidence range might be explained by the different detection reagents and methods. The variable level of different products of the Ct gene results in several circulating immunoreactive isoforms and fragments, giving rise to disparate assay formats and Ct antibody concentrations (13).

The clinicopathologic characteristics of Ct-negative MTC have attracted much attention. Murphy et al. (12) presented a case of MTC in which the tumor size was 35 mm, but RET gene mutation analysis was negative. Similarly, Chernyavsky et al. (19) reported an MTC sized approximately 15 mm, but the RET proto-oncogene mutation assay was negative for mutations in exons 10, 11, 13, 14, 15, and 16. In the three cases reported by Jingzhu et al. (20), the tumor size ranged from 3 to 70 mm, and one patient had three foci. In the case series of Kim et al. (9), the mean tumor size in their 19 patients was only 6.5 mm. Interestingly, our results supported these findings. As the serum Ct level usually increases with tumor size, these findings might indicate that there is an inherent difference between Ct-negative and typical MTC. This difference could be explained by at least four aspects: 1) the mechanism of Ct synthesis may be defective, or alternatively, the storage and/or secreting apparatus could be impaired; 2) a defect in Ct production might be related to dedifferentiation, which does not support the wide range of clinical outcomes in these patients, from long-term survival to rapid progression and death; 3) precursor peptides and aberrant forms of Ct may be produced, resulting in inability to form mature Ct; and 4) serum Ct may degrade rapidly at room temperature owing to the property of high instability (20). Notably, in almost all reported Ct-negative MTC cases, the RET gene mutation test was negative. As this test detects approximately 95% of mutations causative of familial MTC, this finding suggests that Ct-negative MTC is very likely to be sporadic.

CEA is an important tumor marker for gastrointestinal malignancy and MTC. In a recent review, it was found that preoperative CEA values >30 ng/mL were indicative of extra-thyroid disease, while CEA values >100 ng/mL were related to lymph node involvement and distant metastasis. Furthermore, increase in the preoperative CEA values was associated with
higher than that in the Ct-positive group. This result is consistent with previously reported findings. Namely, the rate of achievement of undetectable Ct was found to be independently affected by lymph node metastasis, tumor stage, and tumor size (23); thus, patients with advanced-stage disease are less likely to achieve this goal. Furthermore, Cohen et al. (24) reported postoperative normalization of Ct levels in 97% of patients when the preoperative level was below 50 pg/mL, but the rate decreased to 41.7% when preoperative Ct levels exceeded 50 pg/mL. Other studies have also reported that undetectable Ct was less likely to be achieved in cases of high preoperative Ct levels (5, 25).

Predictors of excellent response in Ct-negative MTC have not been analyzed previously. In the current study, sex was the only significant factor, and male patients were less likely to achieve excellent response. In a previous study, risk factors preventing achievement of undetectable Ct in typical MTC included extrathyroidal tumor involvement, distant metastasis, and positive lymph node disease, while patients’ sex had minimal influence (26). This discrepancy in the results partially supports the unique features of Ct-negative MTC, which requires further molecular research. Furthermore, although major international guidelines recommend total thyroidectomy for MTC of any size to achieve better oncologic outcomes (2, 27, 28), in the present study, the operation type had no influence on the excellent response rate, suggesting that unilateral lobectomy might be suitable for Ct-negative MTC. However, increased postoperative Ct levels were noted in two patients, one of whom underwent unilateral lobectomy. It has been reported that initially nonsecretory MTC may become secretory MTC regardless of the tumor size (11). Although the underlying mechanism remains unknown, this finding highlights the need for regular Ct and CEA level measurements in the follow-up of patients with Ct-negative MTC.

The current study might be the first to describe the characteristics of Ct-negative MTC. Our findings could provide significant insight into the rational management of this rare disease. Nonetheless, the study also had some limitations. First, as a retrospective study, it had inherent bias; second, our sample size was relatively small, which would have decreased the statistical power; third, the underlying molecular mechanism was not analyzed. Therefore, further basic and clinical research is required.

In summary, Ct-negative MTC is rare and unlikely to develop lymph node metastasis. Unilateral lobectomy tends to provide a satisfactory chance of excellent response; however, this requires further validation.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.
Ethics statement

The studies involving human participants were reviewed and approved by Anyang People Hospital. The patients/participants provided their written informed consent to participate in this study.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

References

1. Jabers T, Dadu R, Hu MD. Medullary thyroid carcinoma. Cur Opin Endocrinol Diabetes Obes (2021) 28:540–6. doi:10.1097/MED.0000000000000662
2. Wells SA Jr, Asa SL, Drahle H, Elisei R, Evans DB, Gagel RF, et al. American Thyroid association guidelines task force on medullary thyroid carcinoma. revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid (2015) 25:567–610. doi:10.1089/thy.2014.0335
3. Baldini E, Arlot-Bonnefains Y, Sorrenti S, Mian C, Pelizzo MR, De Antoni E, et al. Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenesis of the MTC6-derived cell line TT. BMC Cancer (2011) 11:411. doi: 10.1186/1471-2407-11-411
4. Wong A, Nabata K, Wiseman SM. Medullary thyroid carcinoma: a narrative historical review. Expert Rev Anticancer Ther (2011) 11:411–23. doi:10.1586/14747207.2011.600041
5. Fanget F, Demarchi MS, Maillard L, Lintis A, Decaussin M, Lifante JC. Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels. Br J Surg (2021) 108:1064–71. doi: 10.1093/bjs/iizt106
6. Viola D, Elisei R. Management of medullary thyroid cancer. Endocr Metab Clin North Am (2019) 48:285–301. doi:10.1016/j.ecl.2018.11.006
7. Sobol RE, Memoli V, Deftos LJ. Hormone-negative, chromogranin a-positive endocrine tumors. N Engl J Med (1989) 320:444–7. doi: 10.1056/NEJM198902233200807
8. Samà MT, Rossetto Giaccherino R, Gallo M, Felicetti F, Maletta F, Bonelli N, et al. Clinical challenges with calcitonin-negative medullary thyroid carcinoma. J Cancer Res Clin Oncol (2016) 142:2023–39. doi:10.1007/s00432-016-2169-5
9. Kim SJ, Yun HJ, Shin SJ, Lee YS, Chang HS. Serum calcitonin-negative medullary thyroid carcinoma: A case series of 19 patients in a single center. Front Endocrinol (Lausanne) (2021) 12:747704. doi: 10.3389/fendo.2021.747704
10. Zhou Q, Yue S, Cheng Y, Jin J, Xu H. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin. Exp Toxicol Pathol (2017) 69:575–9. doi:10.1016/j.etp.2017.05.003
11. Frank-Rase K, Machens A, Leidig-Bruckner G, Leidig-Bruckner G, Machens A, Leidig-Bruckner G, et al. Prevention and clinical spectrum of nonsyecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma. Thyroid (2013) 23:294–300. doi:10.1089/thy.2012.0236
12. Murphy DC, Johnson SJ, Aspinall S. Calcitonin-negative medullary thyroid carcinoma: the ‘triple-negative’ phenotype. Ann R Coll Surg Engl (2020) 102:e63–8. doi:10.1308/rcsann.2020.7118
13. Trimbolet P, Giovannelli L. Serum calcitonin-negative medullary thyroid carcinoma: a systematic review of the literature. Clin Chem Lab Med (2015) 53:1507–14. doi:10.1515/cclm-2015-0058
14. Gambardella C, Offi C, Patrone R, Clarizia G, Mauriello C, Tartaglia E, et al. Calcitonin negative medullary thyroid thyroid (2019) 19(Suppl 1):45. doi:10.1186/s12902-019-0367-2
15. Filimon S, Payne RJ, Black MJ, Hier MP, Mylnarek AM, Forest VI, et al. Calcitonin secretory index and unsuspected nodal disease in medullary thyroid carcinoma. Endocr Pract (2018) 24:460–7. doi:10.4158/EP-2017-0236
16. Ahmed SR, Ball DW. Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment. J Clin Endocrinol Metab (2011) 96:1237–45. doi:10.1210/jc.2010-2359
17. Tuttle RM, Garly I. Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging. Oral Oncol (2013) 49:695–701. doi:10.1016/j.joraloncol.2013.03.043
18. Baptista PF, Fonseca LCM, Carvalho AFC, Silva SNVD, Freitas CRO. Brain metastasis from calcitonin-negative medullary thyroid carcinoma. Ann Endocrinol (Paris) (2022) 83:258–60. doi:10.1016/j.aen.2022.04.015
19. Cheryakovs VS, Farghahi S, Davidson T, Ma L, Barnard N, Amorosa LF, et al. Calcitonin-negative neuroendocrine tumor of the thyroid: a distinct clinical entity. Thyroid (2011) 21:193–6. doi:10.1089/thy.2010.0299
20. Jinghu Z, Xiangqian Z, Min G, Yi P, Jiaodong C, Xinwei Y, et al. Clinical challenges with calcitonin-negative medullary thyroid carcinoma: three case reports and a review of the literature. Ann R Coll Surg Engl (2022) 104:223–30. doi:10.1308/rcsann.2020.7118
21. Passos I, Stefandou E, Meditou-Eythymiou S, Mironidou-Tzouveleki M, Manaki V, Magra V, et al. A review of the significance in measuring preoperative and postoperative calcitonin/midgroomycin antigen (CEA) values in patients with medullary thyroid carcinoma (MTC). Medicina (Kaunas) (2021) 57:609. doi:10.3390/medicina57060609
22. Giovannella L, Crippa S, Cariani L. Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers. Int J Biol Markers (2008) 23:129–31. doi:10.17243/2008000003201122
23. Machens A, Lorenz K, Drahle H. Prediction of biochemical cure in patients with medullary thyroid cancer. Br J Surg (2020) 107:695–704. doi:10.1002/bjs.1.1444
24. Yip DT, Hassan M, Paxioutou-Panyiostou K, Ruan DT, Gawande AA, Gas RD, et al. Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma. Surgery (2011) 150:1168–77. doi:10.1016/j.surg.2011.09.043
25. Cohen R, Campos JM, Salauin C, Heshmati HM, Kramps J, Proye C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d’Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab (2000) 85:919–22. doi:10.1210/jcem.85.2.6556
26. Rowland KJ, Jin LX, Moley JF. Biochemical cure after reoperations for medullary thyroid carcinoma: a meta-analysis. Ann Oncol (2015) 26(2):92–102. doi:10.1093/annonc/mdv387
27. Yu W, Wen T, Qinqhai G, Minghu G, Minghua Z. Expert consensus on the diagnosis and treatment of medullary thyroid carcinoma. in: Chinese thyroid association, the society of thyroid cancer Chinese research hospital association thyroid disease committee, 2020 edition.
28. Zhang D, Colombo C, Sun H, Kim HY, Pino A, de Leo S, et al. Unilateral surgery for medullary thyroid carcinoma. Seeking for clinical practice guidelines. Front Endocrinol (Lausanne) (2022) 13:875875. doi:10.3389/fendo.2022.875875

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher; the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.